Akero Therapeutics

Join us next week as Akero participates in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference. Tune in to the live webcast of the session December 3rd at 9:10 AM ET through the investor relations section of our website. Learn more: https://lnkd.in/evjSMtuR #HealthCONx2024 #EvercoreISI

Greetings from San Diego! #TeamAkero had the pleasure of attending this year’s American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 to connect with leading experts, share our latest data and insights for #EFX, and engage in inspiring discussions about the future of MASH treatment. We're excited to continue advancing EFX through Phase 3 and look forward to seeing you all at future events! #TLM24 #Biotech #Innovation

Are you at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 this weekend? Join us on Sun, 11/17 at 2:00 PM PT for our oral presentation on #EFX week 96 data from our HARMONY study and visit our posters on Mon, 11/18 for insights on the latest trial data and AI-based digital pathology. Learn more: https://lnkd.in/ey-j-uED #TLM24

Today Akero reported Q3 2024 financial results and provided business updates. Read more at: https://lnkd.in/eXyXSfzM

A recent Endpoints News article written by Max Bayer discusses the opportunities for #MASH therapies to co-exist with GLP-1s, potentially offering enhanced benefits for patients struggling with the complex metabolic disorder. In the story, Max Bayer discusses how our lead drug #EFX can work synergistically with GLP-1s based on data from our Phase 2 Cohort D study evaluating patients with #MASH and type 2 diabetes: https://lnkd.in/gZVXhW6E Learn more about Akero: https://akerotx.com/

October is #NationalLiverAwarenessMonth! We recognize the vital role that our liver plays in our overall health and encourage everyone to learn more about metabolic diseases and their risk factors. #MASH is a severe form of #MASLD affecting an estimated 22 million American adults which can progress to cirrhosis, liver failure, cancer, and death. Take the American Liver Foundation’s liver health quiz today to check your risk for fatty liver diseases and know what questions to ask your doctor at your next check up: https://lnkd.in/gNWqRc3F

See you in San Diego for the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024! We’re excited to delve into the latest research on #MASH treatment strategies and share data from our Phase 2b HARMONY clinical trial of #EFX. Don’t miss our oral presentation and 2 late-breaking posters. Read our release to learn more: https://lnkd.in/eqbPRahW #TLM24 #AASLD24

#TeamAkero recently came together for a day of collaboration, innovation, and inspiration. Our onsite meeting was an opportunity for us to align our goals, share insights, and drive forward our mission of developing transformational therapies for metabolic conditions with high unmet need.

Today, our COO and longtime disability rights advocate, Jonathan Young, will have the honor of being the keynote speaker at Bender Leadership Academy’s 2024 #DisabilityMentoring Day Reception in Pittsburgh, PA. Tune in at 6:00 PM EST and join us in celebrating this opportunity to learn and connect as we strive to create a more accessible future for all. https://lnkd.in/eMF65fe6

Don’t miss Akero’s upcoming fireside chat at the H.C. Wainwright & Co., LLC 8th Annual MASH Virtual Conference. Tune in to the live webcast October 7th at 11:00 AM EST through the investor relations section of our website. Register today: https://lnkd.in/ed_T9ncv Watch the live webcast: https://lnkd.in/eqxvWxzq